Schmidt Health Korea, a company specializing in immunotherapeutics, announced on the 27th that it has signed a co-promotion agreement with Daewoong Pharmaceutical for its flagship respiratory infection treatment, Ismigen Seol Hajung.
Through this collaboration, the two companies plan to position Ismigen not just as a respiratory infection treatment, but as an advanced "immune enhancement solution" that overcomes the limitations of standard therapies in the market.
Ismigen is a medication that improves persistent residual symptoms in respiratory diseases such as the common cold, sinusitis, rhinitis, allergies, asthma, chronic cough, bronchitis, COPD (chronic obstructive pulmonary disease), and bronchiectasis. It has established clinical evidence and demonstrated high treatment satisfaction for cardiovascular patients who may experience ischemic exacerbation even from minor colds, adults with chronic inflammatory diseases suffering from weakened immunity, and cancer patients requiring immune cell activation for recurrence management.
Furthermore, Ismigen is characterized by its mechanism that goes beyond mere symptom suppression, aiming to restore and strengthen the body’s natural immune defense system, thereby enabling both prevention and treatment of diseases.
Yoon Doowon, CEO of Schmidt Health Korea, stated, "This collaboration with Daewoong Pharmaceutical holds value beyond simply increasing sales. By leveraging the nation’s top-tier sales network, we aim to widely communicate the value of Ismigen as a 'fundamental immunotherapeutic' to healthcare professionals and patients, and to establish a new standard in the management of respiratory and immune diseases."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
